AbbVie reported that its Phase 1 study of the long‑acting amylin analog ABBV‑295 produced clinically meaningful, dose‑dependent weight loss in adults with a body mass index under 30 kg/m². Across multiple dosing cohorts, the drug achieved 7.8% to 9.8% weight reduction at weeks 12–13, with the most pronounced effect seen in the weekly dosing groups. The study, which evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous ABBV‑295, found the compound to be well tolerated; gastrointestinal adverse events were mild and largely confined to the first six weeks of treatment.
ABBV‑295 operates through a distinct mechanism, activating amylin and calcitonin receptors to promote satiety and delay gastric emptying. This pathway differs from the incretin‑based GLP‑1 and GIP receptor agonists that dominate the current obesity treatment landscape, positioning ABBV‑295 as a potentially differentiated therapeutic option. The positive Phase 1 data therefore represent a significant milestone toward a first‑in‑class obesity therapy and could open a new revenue stream for AbbVie.
AbbVie’s entry into obesity reflects a broader diversification strategy that has seen the company invest $380 million in two new API facilities in Illinois to support future neuroscience and obesity drug production, with operations slated to begin in 2029. The partnership with Gubra, announced in March 2025, formalized AbbVie’s commitment to the obesity field and underscored the company’s intent to expand beyond its traditional immunology and neuroscience platforms.
Markus Rohrwild, CEO of Gubra, said, “We are very encouraged by these clinical results. Obesity continues to be a growing global health challenge, with a well‑recognized need for novel treatment options. These data demonstrate the potential of ABBV‑295 to deliver meaningful body weight reduction with a favorable tolerability profile, supporting its differentiated positioning within the evolving obesity treatment landscape. We are very pleased with these results and we look forward to seeing AbbVie continue the advancement of the asset.” AbbVie’s own leadership echoed this optimism: Robert A. Michael, CEO, noted that the partnership “marks our entry into the obesity field, offering a compelling opportunity based on the potential to address patient needs while also fostering long‑term growth for our company,” and Roopal Thakkar, M.D., Executive Vice President, Research & Development, added that the company “looks forward to advancing the GUB014295 program.”
Analysts highlighted the data as a positive development for AbbVie’s diversification strategy. The results were compared to Eli Lilly’s eloralintide, with commentators noting that direct comparisons are challenging due to differences in study populations and dosing regimens. The weight‑loss figures for ABBV‑295 are competitive within the amylin class, suggesting that the candidate could carve out a niche in the growing obesity market.
Investor sentiment was muted following the announcement, reflecting concerns about valuation and the early stage of the program. The market reaction underscored the cautious approach investors take toward early‑stage obesity candidates, even when clinical data are encouraging.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.